Insights from a Pan India Sero-Epidemiological survey (Phenome-India Cohort) for SARS-CoV2

Naushin, Salwa; Sardana, Viren; Ujjainiya, Rajat; Bhatheja, Nitin; Kutum, Rintu; Bhaskar, Akash Kumar; Pradhan, Shalini; Prakash, Satyartha; Khan, Raju; Rawat, Birendra Singh; Tallapaka, Karthik Bharadwaj; Anumalla, Mahesh; Chandak, Giriraj Ratan; Lahiri, Amit; Kar, Susanta; Mulay, Shrikant Ramesh; Mugale, Madhav Nilakanth; Srivastava, Mrigank; Khan, Shaziya; Srivastava, Anjali; Tomar, Bhawana; Veerapandian, Murugan; Venkatachalam, Ganesh; Vijayakumar, Selvamani Raja; Agarwal, Ajay; Gupta, Dinesh; Halami, Prakash M; Peddha, Muthukumar Serva; Sundaram, Gopinath M; Veeranna, Ravindra P; Pal, Anirban; Agarwal, Vinay Kumar; Maurya, Anil Ku; Singh, Ranvijay Kumar; Raman, Ashok Kumar; Anandasadagopan, Suresh Kumar; Karuppanan, Parimala; Venkatesan, Subramanian; Sardana, Harish Kumar; Kothari, Anamika; Jain, Rishabh; Thakur, Anupama; Parihar, Devendra Singh; Saifi, Anas; Kaur, Jasleen; Kumar, Virendra; Mishra, Avinash; Gogeri, Iranna; Rayasam, Geethavani; Singh, Praveen; Chakraborty, Rahul; Chaturvedi, Gaura; Karunakar, Pinreddy; Yadav, Rohit; Singhmar, Sunanda; Singh, Dayanidhi; Sarkar, Sharmistha; Bhattacharya, Purbasha; Acharya, Sundaram; Singh, Vandana; Verma, Shweta; Soni, Drishti; Seth, Surabhi; Vashisht, Sakshi; Thakran, Sarita; Fatima, Firdaus; Singh, Akash Pratap; Sharma, Akanksha; Sharma, Babita; Subramanian, Manikandan; Padwad, Yogendra S; Hallan, Vipin; Patial, Vikram; Singh, Damanpreet; Tripude, Narendra Vijay; Chakrabarti, Partha; Maity, Sujay Krishna; Ganguly, Dipyaman; Sarkar, Jit; Ramakrishna, Sistla; Kumar, Balthu Narender; Kumar, Kiran A; Gandhi, Sumit G; Jamwal, Piyush Singh; Chouhan, Rekha; Jamwal, Vijay Lakshmi; Kapoor, Nitika; Ghosh, Debashish; Thakkar, Ghanshyam; Subudhi, Umakanta; Sen, Pradip; Chaudhury, Saumya Ray; Kumar, Rashmi; Gupta, Pawan; Tuli, Amit; Sharma, Deepak; Ringe, Rajesh P; D, Amarnarayan; Kulkarni, Mahesh; Shanmugam, Dhansekaran; Dharne, Mahesh S; Dastager, Sayed G; Joshi, Rakesh; Patil, Amita P; Mahajan, Sachin N; Khan, Abujunaid Habib; Wagh, Vasudev; Yadav, Rakesh Kumar; Khilari, Ajinkya; Bhadange, Mayuri; Chaurasiya, Arvindkumar H; Kulsange, Shabda E; Khairnar, Krishna; Paranjape, Shilpa; Kalita, Jatin; Sastry, Narahari G; Phukan, Tridip; Manna, Prasenjit; Romi, Wahengbam; Bharali, Pankaj; Ozah, Dibyajyoti; Sahu, Ravi Kumar; Babu, Elapavalooru VSSK; Sukumaran, Rajeev; Nair, Aiswarya R; Valappil, Prajeesh Kooloth; Puthiyamadam, Anoop; Velayudhanpillai, Adarsh; Chodankar, Kalpana; Damare, Samir; Madhavi, Yennapu; Aggarwal, Ved Varun; Dahiya, Sumit; Agrawal, Anurag; Dash, Debasis; Sengupta, Shantanu

To understand the spread of SARS-CoV2, in August and September 2020, the Council of Scientific and Industrial Research (India) conducted a serosurvey across its constituent laboratories and centers across India. Of 10,427 volunteers, 1058 (10.14%) tested positive for SARS-CoV2 anti-nucleocapsid (anti-NC) antibodies, 95% of which had surrogate neutralization activity. Three-fourth of these recalled no symptoms. Repeat serology tests at 3 (n = 607) and 6 (n = 175) months showed stable anti-NC antibodies but declining neutralization activity. Local seropositivity was higher in densely populated cities and was inversely correlated with a 30-day change in regional test positivity rates (TPRs). Regional seropositivity above 10% was associated with declining TPR. Personal factors associated with higher odds of seropositivity were high-exposure work (odds ratio, 95% confidence interval, p value: 2.23, 1.92–2.59, <0.0001), use of public transport (1.79, 1.43–2.24, <0.0001), not smoking (1.52, 1.16–1.99, 0.0257), non-vegetarian diet (1.67, 1.41–1.99, <0.0001), and B blood group (1.36, 1.15–1.61, 0.001).